Corient Private Wealth
DGX icon

Corient Private Wealth’s Quest Diagnostics DGX Stock Holding History

Corient Private Wealth’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.23M Sell
34,092
-5,233
-13% -$1.03M 0.01% 750
2026
Q1 		$7.56M Buy
39,325
+2,712
+7% +$527K 0.01% 715
2025
Q4 		$6.35M Buy
36,613
+10,466
+40% +$1.91M 0.01% 694
2025
Q3 		$4.98M Buy
26,147
+1,142
+5% +$203K 0.01% 712
2025
Q2 		$4.49M Sell
25,005
-9,292
-27% -$1.61M 0.01% 731
2025
Q1 		$5.8M Sell
34,297
-4,204
-11% -$691K 0.01% 650
2024
Q4 		$5.81M Sell
38,501
-225
-0.6% -$35K 0.01% 657
2024
Q3 		$6.01M Sell
38,726
-23
-0.1% -$3.44K 0.01% 698
2024
Q2 		$5.3M Buy
38,749
+734
+2% +$101K 0.01% 693
2024
Q1 		$5.06M Sell
38,015
-3,398
-8% -$441K 0.01% 704
2023
Q4 		$5.71M Buy
41,413
+5,308
+15% +$698K 0.01% 670
2023
Q3 		$4.4M Sell
36,105
-3,799
-10% -$506K 0.01% 662
2023
Q2 		$5.61M Sell
39,904
-38,531
-49% -$5.31M 0.01% 598
2023
Q1 		$11.1M Buy
78,435
+67,635
+626% +$9.68M 0.03% 418
2022
Q4 		$1.69M Buy
+10,800
New +$1.55M 0.01% 758

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Corient Private Wealth's DGX Position: Q2 2026 in Review

Corient Private Wealth reduced its Quest Diagnostics (DGX) stake by 13% in Q2 2026, selling an estimated $1.03M and leaving 34,092 shares worth $7.23M. The position accounts for 0.01% of the portfolio, ranked #750.

Corient Private Wealth first reported a position in DGX in Q4 2022 and has held it in 15 quarters since. The position peaked at $11.1M in Q1 2023. 1,109 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Corient Private Wealth held 34,092 shares of Quest Diagnostics worth $7.23M as of Q2 2026.
  • Corient Private Wealth sold 5,233 Quest Diagnostics shares in Q2 2026, an estimated $1.03M.
  • Quest Diagnostics made up 0.01% of Corient Private Wealth's portfolio in Q2 2026, its #750 holding.
  • Corient Private Wealth first reported a position in Quest Diagnostics in Q4 2022 and has held it in 15 quarters since.
  • Corient Private Wealth's Quest Diagnostics position peaked at $11.1M in Q1 2023.
  • 1,109 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.